Switzerland
  • Europe
    • FR
    • DE
    • IT
    • ES
    • BE
    • NL
    • LU
    • DK
    • PL
    • UK
  • Switzerland
    • Basel
    • Bern
    • Geneva
    • Lausanne
    • Zürich
  • Schweiz
  • Suisse
  • Alps
  • Business
    • ABB
    • Chubb
    • Glencore
    • Nestlé
    • Novartis
    • Roche
    • UBS
    • Vitol
    • Zurich Insurance
  • NATO
  • US
  • Africa
  • Afrique

Categories

  • ABB
  • Alps
  • Basel
  • Bern
  • Chubb
  • Geneva
  • Glencore
  • Lausanne
  • Nestlé
  • Novartis
  • Roche
  • Switzerland
  • UBS
  • Vitol
  • Zürich
  • Zurich Insurance
Switzerland
  • Europe
    • FR
    • DE
    • IT
    • ES
    • BE
    • NL
    • LU
    • DK
    • PL
    • UK
  • Switzerland
    • Basel
    • Bern
    • Geneva
    • Lausanne
    • Zürich
  • Schweiz
  • Suisse
  • Alps
  • Business
    • ABB
    • Chubb
    • Glencore
    • Nestlé
    • Novartis
    • Roche
    • UBS
    • Vitol
    • Zurich Insurance
  • NATO
  • US
  • Africa
  • Afrique

Browsing Tag

Phase III

24 posts
RRoche
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong 2025 results with 7% sales growth
Read More

Roche announces positive phase III results for Gazyva/Gazyvaro in primary membranous nephropathy, marking a significant milestone in this autoimmune disease

  • 2026-02-18
F. Hoffmann-La Roche Ltd MAJESTY, the first global phase III study in primary membranous nephropathy, met its primary…
RRoche
Roche fenebrutinib Phase III hits PPMS disability goal
Read More

Roche’s Tecentriq Cuts Death Risk 41% in ctDNA‑guided MIBC

  • 2026-02-17
Roche (OTCQX: RHHBY) reported positive phase III IMvigor011 results for Tecentriq (atezolizumab) as…
RRoche
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong 2025 results with 7% sales growth
Read More

Roche announces positive phase III results for Gazyva/Gazyvaro in primary membranous nephropathy, marking a significant milestone in this autoimmune disease

  • 2026-02-16
F. Hoffmann-La Roche Ltd MAJESTY, the first global phase III study in primary membranous nephropathy, met its primary…
RRoche
Roche eyes Gazyva label expansion on positive Phase III kidney disease data
Read More

Roche eyes Gazyva label expansion on positive Phase III kidney disease data

  • 2026-02-16
Roche is heading to regulators after its blockbuster kidney disease candidate, Gazyva (obinutuzumab), met its primary endpoint during…
RRoche
Roche fenebrutinib Phase III hits PPMS disability goal
Read More

Roche Gazyva phase III remission win in kidney disease

  • 2026-02-16
Roche (OTCQX:RHHBY) announced that the phase III MAJESTY study in adults with primary…
RRoche
Roche announces positive phase III results for Gazyva/Gazyvaro in primary membranous nephropathy, marking a significant milestone in this autoimmune disease
Read More

Roche announces positive phase III results for Gazyva/Gazyvaro in primary membranous nephropathy, marking a significant milestone in this autoimmune disease

  • 2026-02-16
F. Hoffmann-La Roche Ltd MAJESTY, the first global phase III study in primary membranous nephropathy, met its primary…
RRoche
Examining Valuation After Recent Share Price Momentum
Read More

Roche’s CT-388 Obesity Data Tests New Growth Pillar Potential

  • 2026-02-16
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply…
RRoche
Roche Holding (SWX:ROG) Valuation Check After Recent Share Price Momentum And Conflicting Fair Value Views
Read More

Roche Obesity Drug CT-388 Phase II Results Reshape Growth Narrative

  • 2026-02-14
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St’s investing ideas for…
RRoche
Giredestrant structure
Read More

Roche presents details on breast cancer pill giredestrant

  • 2026-02-14
Roche has unveiled detailed data for its oral selective estrogen receptor degrader (SERD), giredestrant, at the 2025 San…
RRoche
Roche fenebrutinib Phase III hits PPMS disability goal
Read More

Roche’s Columvi combo doubles survival in three-year DLBCL study

  • 2026-02-13
Roche (RHHBY) reported three-year follow-up from the phase III STARGLO study in relapsed/refractory…
RRoche
Roche fenebrutinib Phase III hits PPMS disability goal
Read More

Roche’s giredestrant cuts recurrence, death risk 30% in early breast cancer

  • 2026-02-13
Roche (OTCQX: RHHBY) announced positive phase III lidERA results showing investigational oral SERD…
RRoche
Roche fenebrutinib Phase III hits PPMS disability goal
Read More

Roche fenebrutinib Phase III hits PPMS disability goal

  • 2026-02-11
Roche (OTCQX: RHHBY) reported Phase III FENtrepid results showing investigational oral BTK inhibitor…
Switzerland
www.europesays.com